Favipiravir
Brand Formulations & Prices
24 brands sorted by unit price
Favipira
Akarvia
Biofavi
Fapiravir
Fapravir
Favilar
Favinil
Favipir
Favira
Faviravir
Favirest
Favitab
Favivir
Fluvigan
Fravir
Ivrenas
Piravir
Piravix
Rotagan
Toyavir
Unifav
Verigan
Viraflu
Favigan
📖 Official Clinical Monograph
DGDA Approved Prescribing GuidelinesTreatment of novel or re-emerging pandemic influenza virus infections (limited to cases in which other influenza antiviral drugs are ineffective or not sufficiently effective).
The usual adult dosage is 1600 mg of Favipiravir administered orally twice daily on Day 1, followed by 600 mg orally twice daily from Day 2 to Day 5 or as directed by physicians. The total treatment duration should be 5 days.
Favipiravir is contraindicated for pregnant women and women who may possibly be pregnant.
Most common side effects are Diarrhea and increase of blood uric acid levels.
Akarvia should not be given in pregnant women, requirement of the confirmation of non-pregnancy in women of childbearing potential before use, thorough contraception measures from the start of the treatment to 7 days after the end of the treatment. Caution should be taken for Hepatic and renal impaired patient or use Akarvia as per the direction of registered Physician
Favipiravir is a new antiviral drug against influenza. It is metabolized into favipiravir ribosyl triphosphate (favipiravir RTP) by an intracellular enzyme, and favipiravir RTP selectively inhibits RNA polymerase (RNA-dependent RNA polymerase) of the influenza virus, preventing replication of the influenza virus. It is a drug with a mechanism of action different from that of the existing influenza antiviral drugs and effective against all types and sub-types of human influenza A, B, and C viruses in vitro, showing a wide range of anti-viral activity against various influenza virus strains including avian and swine viruses.